Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 5 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
BMC Med. 2024 Jan 29;22(1):42. doi: 10.1186/s12916-024-03257-7.
BMC Med. 2024.
PMID: 38281914
Free PMC article.
Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade.
Sun B, Xun Z, Zhang N, Liu K, Chen X, Zhao H.
Sun B, et al.
Cancer Cell Int. 2023 Dec 8;23(1):313. doi: 10.1186/s12935-023-03158-4.
Cancer Cell Int. 2023.
PMID: 38066642
Free PMC article.
Review.
Item in Clipboard
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, Zhu C, Ning C, Zhang X, Xue J, Zhang L, Piao M, Wang M, Yang X, Lu L, Zhao H.
Chao J, et al.
Cancer Immunol Immunother. 2023 Nov;72(11):3717-3726. doi: 10.1007/s00262-023-03523-2. Epub 2023 Oct 3.
Cancer Immunol Immunother. 2023.
PMID: 37787790
Free PMC article.
Item in Clipboard
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, Yang X, Xun Z, Chao J, Long J, Sang X, Zhu Z, Zhao H.
Zhu C, et al.
Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29.
Cancer Immunol Immunother. 2023.
PMID: 37247023
Free PMC article.
Item in Clipboard
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Wang Y, Yang X, Wang Y, Xue J, Zhang N, Yang X, Cong N, Zhang J, Zhu C, Zhang L, Hou X, Zhao H.
Wang Y, et al.
Cancer Immunol Immunother. 2023 Jul;72(7):2197-2204. doi: 10.1007/s00262-023-03399-2. Epub 2023 Mar 1.
Cancer Immunol Immunother. 2023.
PMID: 36856834
Free PMC article.
Item in Clipboard
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H.
Yang X, et al.
Hepatol Int. 2023 Jun;17(3):709-719. doi: 10.1007/s12072-022-10480-y. Epub 2023 Feb 8.
Hepatol Int. 2023.
PMID: 36753026
Free PMC article.
Item in Clipboard
Cite
Cite